journal
MENU ▼
Read by QxMD icon Read
search

Journal of Rheumatology. Supplement

journal
https://www.readbyqxmd.com/read/29858357/proceedings-of-the-2017-grappa-collaborative-research-network-meeting
#1
Deepak R Jadon, Vinod Chandran, Carmel Stober, Alexis Ogdie, April W Armstrong, Kristina Callis Duffin, Dafna D Gladman, Philip S Helliwell, Denis O'Sullivan, Maarten de Wit, Oliver FitzGerald, Christopher T Ritchlin
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Collaborative Research Network (CRN) is an endeavor that aims to address gaps in the knowledge of the etiopathogenesis and management of psoriatic disease by best using the large community of experienced investigators who are already collecting rich clinical phenotype data and biologic samples using validated techniques. Exemplar rheumatology and dermatology projects will inform strategies to implement the CRN, while input and funding from government organizations, charities, and industry will shape the CRN...
June 2018: Journal of Rheumatology. Supplement
https://www.readbyqxmd.com/read/29858356/the-patient-research-partner-network-matures-a-report-from-the-grappa-2017-annual-meeting
#2
Niti Goel, Denis O'Sullivan, Maarten de Wit, Chris A Lindsay, Heidi Bertheussen, John Latella, Jeffrey Chau, Roland MacDonald, Suzanne Grieb, Ingrid Steinkoenig, Willemina Campbell
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) has reached the third of 5 stages of organizational maturity regarding incorporating patient research partners (PRP) into psoriatic arthritis (PsA) and psoriasis research and educational efforts. Herein, we report the involvement of PRP at the GRAPPA 2017 annual meeting and plans for future PRP engagement.
June 2018: Journal of Rheumatology. Supplement
https://www.readbyqxmd.com/read/29858355/grappa-2017-project-report
#3
Kristina Callis Duffin, Oliver FitzGerald, Artie Kavanaugh, Philip J Mease, Joseph F Merola, Alexis Ogdie, Denis O'Sullivan, Soumya M Reddy, Christopher T Ritchlin, Laura C Coates
At the 2017 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members received updates on several ongoing educational and research efforts. Among them were updates on GRAPPA's continued education efforts; GRAPPA's continued research efforts, including the Biomarker Project, a collaborative research effort to identify and study biomarkers of joint damage; treatment recommendations, including recommendations and core principles related to biosimilars; efforts to update GRAPPA's Website and to create a GRAPPA smart-phone application (app); and the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network...
June 2018: Journal of Rheumatology. Supplement
https://www.readbyqxmd.com/read/29858354/options-for-assessing-joints-and-entheses-in-psoriatic-arthritis-by-ultrasonography-and-magnetic-resonance-imaging-how-to-move-forward
#4
Lihi Eder, Sibel Z Aydin, Gurjit S Kaeley, Walter P Maksymowych, Mikkel Østergaard
Psoriatic arthritis (PsA) is a heterogeneous disease with various manifestations of musculoskeletal inflammation. Recent advances in imaging, including ultrasound (US) and magnetic resonance imaging (MRI), allow for the accurate evaluation of the extent of inflammation and damage in the peripheral joints, spine, and entheses. The development and validation of outcome measures are critical steps in creating standardized evaluations of musculoskeletal inflammation and damage in psoriatic patients. At the 2017 meeting of the Group for Research and Assessment of Psoriasis and PsA (GRAPPA), recent work on outcome measures from the GRAPPA US and MRI working groups was summarized...
June 2018: Journal of Rheumatology. Supplement
https://www.readbyqxmd.com/read/29858353/report-of-the-skin-research-working-groups-from-the-grappa-2017-annual-meeting
#5
Alice Bendix Gottlieb, Laura C Coates, Leonieke J J van Mens, April W Armstrong, Joseph F Merola
At the 2017 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), the International Dermatology Outcome Measures (IDEOM) psoriasis working group presented an overview of its cutaneous domain of psoriatic arthritis (PsA) projects. First, the group presented an overview of IDEOM's work to establish psoriasis outcome measures that satisfy the needs of all those involved. Second, the group discussed replacements for the Psoriasis Area and Severity Index (PASI) that can be used in clinical practice, including data that support the use of the physician's global assessment × body surface area measurement score as a PASI surrogate...
June 2018: Journal of Rheumatology. Supplement
https://www.readbyqxmd.com/read/29858352/the-role-of-the-microbiome-in-gut-and-joint-inflammation-in-psoriatic-arthritis-and-spondyloarthritis
#6
Elisabeth Gilis, Céline Mortier, Koen Venken, Karlijn Debusschere, Lars Vereecke, Dirk Elewaut
Spondyloarthritis (SpA) encompasses a group of diseases characterized by an inflammatory arthritis involving both joints and entheses. However, extraarticular symptoms constitute a large element of the pathology and should not be underestimated. Microscopic gut inflammation is observed in 50% of patients with SpA and has been linked to disease activity, underscoring the effect of gut inflammation in SpA. In this review, we discuss the influence of gut microbiota on SpA pathogenesis. A change in microbiota composition has been linked to the development of various inflammatory arthritides, and dysbiosis is a potential factor in the pathogenesis of multiple inflammatory diseases...
June 2018: Journal of Rheumatology. Supplement
https://www.readbyqxmd.com/read/29858351/the-microbiome-in-psoriasis-and-psoriatic-arthritis-joints
#7
Jose U Scher
The microbiome is a known and established immunomodulator of many inflammatory disorders, including psoriasis and psoriatic arthritis. Microbes co-evolved with their human hosts and provide them with nutritional, metabolic, and immunologic support. An accumulating body of evidence has revealed that psoriatic diseases are characterized by a state of intestinal dysbiosis, which has been linked to a decrease in beneficial commensals and fatty acids. This has been shown in both animal models and human samples, and multiple studies have addressed the physiological and potentially pathogenic role of intestinal and cutaneous microbes in human health and disease...
June 2018: Journal of Rheumatology. Supplement
https://www.readbyqxmd.com/read/29858350/the-microbiome-in-psoriasis-and-psoriatic-arthritis-the-skin-perspective
#8
Hok Bing Thio
Psoriasis is a chronic, inflammatory immune-mediated skin disease that affects about 2% of the world's population. In 20% of patients with psoriasis, the characteristic skin lesions are accompanied by psoriatic arthritis (PsA). Psoriasis arises in genetically predisposed individuals who have a dysregulated immune response to various environmental factors. The human body is home to many microbial species, and both the skin and the gut microbiome influence the development and function of immune tissue development and function...
June 2018: Journal of Rheumatology. Supplement
https://www.readbyqxmd.com/read/29858349/the-benefits-and-challenges-of-setting-up-a-longitudinal-psoriatic-arthritis-database
#9
Dafna D Gladman, Laura C Coates, Deepak R Jadon, William Tillett, Philip J Mease, Marijn Vis
The members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) have shown great interest in developing a common GRAPPA database. To address this interest, GRAPPA included a symposium at its 2017 annual meeting to examine the concepts of registries and databases. At this symposium, examples of existing databases were reviewed, and their challenges and achievements were discussed.
June 2018: Journal of Rheumatology. Supplement
https://www.readbyqxmd.com/read/29858348/content-and-face-validity-and-feasibility-of-5-candidate-instruments-for-psoriatic-arthritis-randomized-controlled-trials-the-psa-omeract-core-set-workshop-at-the-grappa-2017-annual-meeting
#10
Richard Holland, William Tillett, Alexis Ogdie, Ying Y Leung, Dafna D Gladman, Kristina Callis Duffin, Laura C Coates, Philip J Mease, Lihi Eder, Vibeke Strand, Musaab Elmamoun, Pil Højgaard, Jeffrey Chau, Maarten de Wit, Niti Goel, Chris A Lindsay, Oliver FitzGerald, Bev Shea, Dorcas Beaton, Ana-Maria Orbai
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Core Set working group is in the process of selecting core instruments for PsA clinical trials. During a 2-h workshop and breakout group discussions at the GRAPPA 2017 annual meeting in Amsterdam, the Netherlands, participants discussed the first set of candidate instruments to be taken through the OMERACT Filter 2.1 instrument selection process: 66/68 swollen/tender joint count (66/68JC), Spondyloarthritis Consortium of Canada (SPARCC) enthesitis index, patient's global assessment (GRAPPA and OMERACT formulations), Health Assessment Questionnaire-Disability Index (HAQ-DI), Psoriatic Arthritis Impact of Disease (PsAID) questionnaires 9 and 12, and Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue...
June 2018: Journal of Rheumatology. Supplement
https://www.readbyqxmd.com/read/29858347/juvenile-psoriatic-arthritis-a-report-from-the-grappa-2017-annual-meeting
#11
Devy Zisman, Matthew L Stoll, Yonatan Butbul Aviel, Elizabeth D Mellins
Juvenile psoriatic arthritis (JPsA), a subtype of juvenile idiopathic arthritis (JIA), constitutes 5% of JIA. The literature is inconsistent regarding features of JPsA, and physicians debate whether it is a distinct entity within JIA. A biphasic age of onset distribution has been noted. Early-onset disease is characterized by female predominance, small joint involvement, dactylitis, and positive antinuclear antibodies. Late-onset JPsA resembles adult-onset psoriatic arthritis (PsA), with male predominance, psoriasis, enthesitis, and axial disease...
June 2018: Journal of Rheumatology. Supplement
https://www.readbyqxmd.com/read/29858346/grappa-trainees-symposium-2017-a-report-from-the-grappa-2017-annual-meeting
#12
Victoria Furer, Julia Manasson, Wolf-Henning Boehncke, Christopher T Ritchlin
At the 2017 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) in Amsterdam, the Netherlands, a trainees symposium was held. Rheumatology and dermatology trainees engaged in psoriasis or psoriatic arthritis research presented their work. This report briefly reviews 6 oral presentations and 25 posters presented at the meeting.
June 2018: Journal of Rheumatology. Supplement
https://www.readbyqxmd.com/read/29858345/prologue-2017-annual-meeting-of-the-group-for-research-and-assessment-of-psoriasis-and-psoriatic-arthritis-grappa
#13
Philip S Helliwell, Dafna D Gladman, Alice B Gottlieb
The 2017 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held in Amsterdam, the Netherlands, and was attended by rheumatologists, dermatologists, representatives of biopharmaceutical companies, and patients. As in previous years, GRAPPA members held a symposium for trainees to discuss their research in psoriatic disease with experts in the field. Other subjects featured during the annual meeting included a discussion of the history, clinical features, controversies, and immunogenetics of juvenile psoriatic arthritis; updates from working groups in Outcome Measures in Rheumatology and International Dermatology Outcome Measures; a discussion of the benefits and challenges of setting up a longitudinal psoriatic arthritis (PsA) database; 3 separate discussions of the effects of the microbiome on skin and joints in psoriasis and PsA; a discussion of options for assessing joints and entheses in PsA by ultrasonography and magnetic resonance imaging; an update on GRAPPA's research and educational projects; a discussion of patient centricity, including the incorporation of patient research partners (PRP) into psoriasis and PsA research and educational efforts, from GRAPPA's PRP; and a discussion of the GRAPPA-Collaborative Research Network's inaugural meeting...
June 2018: Journal of Rheumatology. Supplement
https://www.readbyqxmd.com/read/26523065/obituary-professor-antonio-spadaro
#14
Guido Valesini, Ignazio Olivieri
No abstract text is available yet for this article.
November 2015: Journal of Rheumatology. Supplement
https://www.readbyqxmd.com/read/26523064/role-of-agents-other-than-tumor-necrosis-factor-blockers-in-the-treatment-of-psoriatic-arthritis
#15
REVIEW
Fabiola Atzeni, Luisa Costa, Francesco Caso, Raffaele Scarpa, Piercarlo Sarzi-Puttini
Psoriatic arthritis (PsA) is a systemic inflammatory disease characterized by possible peripheral and axial joint involvement, enthesitis, dactylitis, and skin and nail disease. It affects up to one-third of psoriatic patients, and may be associated with comorbidities such as cardiovascular and metabolic diseases. The usually prescribed initial treatment of moderate-severe PsA is methotrexate, which may be accompanied or replaced by a tumor necrosis factor (TNF) inhibitor such as etanercept, infliximab, or adalimumab...
November 2015: Journal of Rheumatology. Supplement
https://www.readbyqxmd.com/read/26523063/the-role-of-tumor-necrosis-factor-%C3%AE-blockers-in-psoriatic-disease-therapeutic-options-in-psoriatic-arthritis
#16
REVIEW
Olga Addimanda, Niccolò Possemato, Andrea Caruso, Nicolò Pipitone, Carlo Salvarani
Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting peripheral and axial joints, usually associated with psoriasis (PsO) and involving various systems and organs (eye inflammation, such as uveitis; and involvement of nail and enthesis), and it usually requires a multidisciplinary treatment approach. Tumor necrosis factor-α (TNF-α) is overexpressed in psoriatic synovium and skin plaques and its selective inhibition by anti-TNF-α agents has been demonstrated to reduce TNF-α levels in the articular environment, reversing the synovial hyperproliferative phenotype...
November 2015: Journal of Rheumatology. Supplement
https://www.readbyqxmd.com/read/26523062/new-approaches-in-tumor-necrosis-factor-antagonism-for-the-treatment-of-psoriatic-arthritis-certolizumab-pegol
#17
REVIEW
Alberto Cauli, Matteo Piga, Ennio Lubrano, Antonio Marchesoni, Alberto Floris, Alessandro Mathieu
The pathogenesis of psoriatic arthritis (PsA) is still under discussion but great advances have been made in the last 2 decades that confirm the central role of tumor necrosis factor-α (TNF-α) in its inflammatory milieu. New therapeutic approaches have been proposed, and new molecules with anti-TNF-α activity have been chemically altered to improve their pharmacological properties. Certolizumab pegol (CZP) is a PEGylated Fc-free anti-TNF that has been shown clinically to be effective in the treatment of rheumatoid arthritis (RA), skin psoriasis, and PsA...
November 2015: Journal of Rheumatology. Supplement
https://www.readbyqxmd.com/read/26523061/disease-modifying-antirheumatic-drugs-dmard-and-combination-therapy-of-conventional-dmard-in-patients-with-spondyloarthritis-and-psoriatic-arthritis-with-axial-involvement
#18
REVIEW
Davide Simone, Marcin Nowik, Elisa Gremese, Gianfranco F Ferraccioli
Treatment with nonsteroidal antiinflammatory drugs (NSAID) is the recommended first-line therapy in patients with axial spondyloarthritis (axSpA); and for those patients who have persistently active disease, the introduction of tumor necrosis factor-α (TNF-α) inhibitors is indicated. Conventional nonbiological disease-modifying antirheumatic drugs (DMARD), although effective and used in clinical practice for peripheral arthritis, are not recommended. Few studies have been conducted with the aim of evaluating the effect of conventional DMARD, either alone or in combination, in axSpA...
November 2015: Journal of Rheumatology. Supplement
https://www.readbyqxmd.com/read/26523060/psoriatic-disease-update-on-traditional-disease-modifying-antirheumatic-drugs
#19
REVIEW
Antonio Marchesoni, Ennio Lubrano, Alberto Cauli, Massimo Ricci, Maria Manara
We present an update on the effects of methotrexate (MTX), sulfasalazine (SSZ), leflunomide (LEF), and cyclosporine (CSA) in psoriatic arthritis (PsA) by reviewing data published from January 2010 to June 2014. The most relevant study on MTX, the Methotrexate In Psoriatic Arthritis (MIPA) trial, did not show a significant difference between this drug and placebo in improving peripheral synovitis. The trial, however, had several limitations. A cohort study on a small number of patients found that MTX does not inhibit radiographic progression...
November 2015: Journal of Rheumatology. Supplement
https://www.readbyqxmd.com/read/26523059/concept-of-remission-in-chronic-plaque-psoriasis
#20
REVIEW
Paolo Gisondi, Marco Di Mercurio, Luca Idolazzi, Giampiero Girolomoni
Psoriasis is a lifelong chronic inflammatory disease affecting 2-3% of the worldwide population. Current understanding of the pathogenesis of psoriasis assigns central importance to an interaction between acquired and innate immunity. The disease is characterized by a series of linked cellular changes in the skin, including hyperplasia of epidermal keratinocytes, angiogenesis, and infiltration of T lymphocytes, neutrophils, and other types of leukocytes in the affected skin. Plaque psoriasis is the most common clinical form and is characterized by red and scaly plaques generally localized at extensor sites such as elbows and knees...
November 2015: Journal of Rheumatology. Supplement
journal
journal
27400
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"